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54 The Journal of Thoracic and Cardiobjectives: Extracorporeal membrane oxygenation (ECMO) for severe graft failure
fter lung transplantation is accepted immediately postoperatively; extending its use is
ontroversial. We evaluated our post–lung transplant ECMO experience, which in-
luded extended indication, to (1) determine its prevalence, risk factors, indications, and
iming, (2) compare complications and outcomes of these patients with those not
equiring it, and (3) identify risk factors, including indications, for mortality.
ethods: From February 1990 to October 2005, 474 patients underwent lung
ransplantation; postoperative ECMO support was instituted for severe graft failure
3 times in 22 patients (4.0%). Indications for ECMO and its timing were obtained
y reviewing medical records and survival by systematic follow-up.
esults: No factor evaluated predicted severe graft failure leading to ECMO. The
ost common indication for ECMO was early graft failure (13 patients); however,
t was also used for pneumonia or sepsis (6) and acute rejection (4). ECMO was
nitiated at a median arterial oxygen tension/inspired oxygen fraction of 59 at a
edian of 2 days postoperatively and was maintained for a median of 4 days. The
ost common complications were renal failure (57%) and bleeding (43%). ECMO
as effective in salvaging patients with rejection and early graft failure (survival at
, 3, 6, and 12 months: 62%, 54%, 49%, and 41%), but ineffective for pneumonia
r sepsis (survival at these intervals: 9%, 4%, 4%, and 3%).
onclusions: ECMO can be extended beyond early severe graft failure to acute
ejection and can be considered after the immediate postoperative period. Survival
fter ECMO in patients with pneumonia or sepsis is poor.
evere graft failure, characterized by impaired gas exchange, is uncommon
after lung transplantation but carries high mortality.1 Extracorporeal mem-
brane oxygenation (ECMO) may be necessary to provide lifesaving support
hen maximal conventional therapy for cardiorespiratory support is inadequate to
aintain oxygenation and perfusion.2 Survival after ECMO depends on indication,
echnique, and timing.3-5 Furthermore, although ECMO is now accepted for severe,
mmediate postoperative graft failure, extending its use to other indications is
ontroversial. Therefore, to guide future use, we evaluated our experience with
ost–lung transplant ECMO, which includes extended indications, to (1) determine
ts prevalence, risk factors, indications, and timing, (2) compare complications and
vascular Surgery ● October 2006
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TXutcomes of these patients with those not requiring it, and
3) identify risk factors, including indications, for mortality.
atients and Methods
atients
rom February 1990 to October 2005, 474 patients underwent
ingle or double lung transplantation for end-stage lung disease at
leveland Clinic. Data were extracted from the Unified Transplant
egistry, which has been approved for research by the Institutional
eview Board of Cleveland Clinic. The Institutional Review
oard approved supplemental review of medical records.
CMO
Support. ECMO was initiated 23 times in 22 patients (4.0%),
hen oxygenation, ventilation, and tissue perfusion were unable to
e supported through conventional methods, including ventilator
upport with 100% inspired oxygen fraction, pharmacologic pa-
alysis, nitric oxide, high positive end-expiratory pressure, and
asopressors. Median arterial oxygen tension/inspired oxygen
raction was 59 at institution of ECMO (15th and 85th percentiles,
4 and 81), which improved to 164 after ECMO was initiated (15th
nd 85th percentiles, 81 and 443). Cannulation was peripheral in
0 cases (87%), central in 2 (9%), and combined in 1 (4%). ECMO
echnique was venoarterial (VA) in 12 (52%) and venovenous
VV) in 11 (48%), based on surgeon preference. As a general rule,
A ECMO was used to support patients with hemodynamic col-
apse in addition to respiratory failure, and VV ECMO was used
or all other patients, without regard to pulmonary artery pressures.
edian pulmonary artery systolic pressure was 49 mm Hg at
nstitution of ECMO (15th and 85th percentiles, 27 and 66 mm
g), which improved to 37 mm Hg after ECMO was initiated
15th and 85th percentiles, 25 and 49 mm Hg).
Circuit. The ECMO circuit has been described previously.6 In
rief, peripheral or central access was established via wire-
einforced thin-walled polyurethane cannulas (Edwards LifeSciences,
rvine, Calif). The circuit was driven by a centrifugal pump (BP80,
edtronic-BioMedicus, Eden Prairie, Minn) through heparin-coated
ubing (Carmeda, Medtronic) and either a hollow-fiber oxygenator
AFFINITY NT, Medtronic) or Maxima-Plus PRF oxygenator
Medtronic) before its discontinuation. All components were heparin
oated. Four peripheral cannulas were placed percutaneously, with the
emainder being placed by cutdown. Sizes ranged from 16F to 24F.
istal arterial cannulation was used in 2 patients.
Conduct. Systemic heparinization was used with a target ac-
ivated clotting time of 180 to 250 seconds. Flows were maintained
etween 2.5 and 3.5 L · min1. Decision to wean from ECMO
as based on radiographic improvement, improved oxygenation,
Abbreviations and Acronyms
ECMO extracorporeal membrane oxygenation
PRA  panel reactive antibody
VA  venoarterial
VV  venovenousncreased graft compliance, and improved hemodynamics. d
The Journal of Thoracicisk Factors for Severe Graft Failure Leading to
CMO
ultivariable logistic regression was used for identifying donor
nd recipient variables (Appendix) associated with ECMO. The
rocess began with initial screening to ensure that at least 5 ECMO
vents were associated with each dichotomous variable.
Bootstrap aggregation (bagging) was used for variable selec-
ion.7,8 In brief, automated stepwise variable selection with P for
nclusion of .1 was performed on 1000 bootstrap samples, and the
esults were aggregated both by individual factors and by clusters
f related factors (such as candidate transformations of scale of
ontinuous and ordered variables). Those appearing in 50% or
ore of the analyses (median rule) were considered reliably sta-
istically significant at P  .1.
tiology of Graft Failure Necessitating ECMO
hart review, review of cultures, biopsy tissues, and clinical
mpressions of the lung transplant team at time of instituting
CMO were used to categorize etiology of graft failure as
ollows: (1) early graft failure, if failure occurred within the
rst 48 hours of transplant and was due to either an implantation
esponse or a technical problem that was identified and cor-
ected; (2) acute rejection, if there was a clinical impression of
ejection driving graft failure, usually documented by trans-
ronchial biopsies; or (3) pneumonia or sepsis, if the clinical
mpression of the transplant team was infection driving graft
ailure, with the criteria being purulent bronchoscopy, positive
ultures, fever, and leukocytosis.
iming and Duration of ECMO
iming of ECMO was calculated as interval from date of operation
o date of instituting ECMO. Duration of ECMO was calculated as
nterval from date of instituting ECMO until its removal or death
n ECMO.
utcomes
rimary outcome was all-cause mortality. Vital status was obtained by
ross-sectional follow-up. Mean follow-up duration was 0.73  1.2
ears, with 5 of 22 patients (23%) followed for more than 1 year. A
otal of 16.7 patient-years of data was available for analysis. Survival
stimates after ECMO were obtained by the Kaplan-Meier method
nd a parametric multiphase survival model.9 Secondary outcomes
ere in-hospital complications of ECMO.
redictors of Mortality
ight variables were used to identify predictors of mortality after
CMO: (1) date of transplant, (2) single versus double lung
ransplant, (3-5) etiology of severe graft failure (early graft failure,
cute rejection, pneumonia, or sepsis), (6) timing of ECMO, (7)
A versus VV cannulation, and (8) duration of ECMO. Variable
election was as previously described.
esults
isk Factors for Severe Graft Failure Leading to
CMO
e were unable to identify reliably either recipient or donoremographic, pretransplant clinical, or transplant variables
and Cardiovascular Surgery ● Volume 132, Number 4 955
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TXABLE 1. Recipient, donor, and transplant characteristics for ECMO and no-ECMO groups
haracteristic
ECMO
P
Yes (n  22) No (n  452)
n* No. % n* No. %
ecipient
Demography
Age (y), mean  SD 22 45 11 452 47  13 .17
Female 22 15 68 452 224 50 .09
Race
Caucasian 22 21 95 448 410 92 .5
Other 22 1 4.5 448 38 8 .5
Height (cm), mean  SD 19 166 12 425 167 11 .4
Weight (kg), mean  SD 21 65 21 444 68  17 .3
BSA (m2), mean  SD 18 1.7 0.3 418 1.8 0.3 .3
BMI (kg · m-2), mean  SD 18 24 5.5 418 24  5.2 .9
Comorbidity
Smoking 14 8 57 306 202 66 .5
Hypertension 18 6 33 387 75 19 .15
Underlying disease
COPD/emphysema 22 7 32 452 171 38 .6
Idiopathic pulmonary fibrosis 22 5 23 452 67 15 .3
Cystic fibrosis 22 4 18 452 78 17 .9
A1A deficiency 22 2 9.1 452 39 8.6 .9
Bronchiectasis 22 1 4.6 452 10 2.2 .5
Eisenmenger disease 22 1 4.6 452 6 1.3 .2
Primary pulmonary hypertension 22 1 4.6 452 22 4.9 .9
Sarcoidosis 22 0 0 452 18 4.0 .3
Immunologic factors
PRA 21 2.2 4.6 448 1.9 7.7 — .07
Blood type
A 21 11 52 443 199 45 .5
O 21 7 33 443 194 44 .3
B 21 3 14 443 50 11 .7
AB 21 0 0 443 0 0 —
Rh factor
Positive 21 19 90 414 348 84 .4
Negative 21 2 9.5 414 66 16 .4
onor
Demography
Age (y), mean  SD 19 35 11 426 35  15 .9
Female 21 11 52 446 221 50 .8
Race
Caucasian 21 19 90 449 391 87 .6
Other 21 2 9.5 449 58 13 .6
Height (cm), mean  SD 22 167 13 447 169 12 .3
Weight (kg), mean  SD 21 68 18 446 71  20 .4
BSA (m2), mean  SD 21 1.8 0.3 446 1.8 0.3 .4
BMI (kg · m2), mean  SD 21 24 4.9 446 25  5.9 .8
Comorbidity
Hypertension 18 3 17 381 68 18 .9
Cause of death
Cerebral bleeding 22 5 23 446 121 27 .6
CNS tumor 22 1 4.6 446 8 1.8 .4
CVA/stroke 22 5 23 446 92 21 .8
Head trauma 22 10 45 446 188 42 .8Immunologic factors
56 The Journal of Thoracic and Cardiovascular Surgery ● October 2006
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TXhat predicted severe graft failure leading to ECMO (Table
). Variables not found to be associated with severe graft
ailure included cold ischemic time, panel reactive antibody
PRA) level, and donor-to-recipient size match.
tiology of Graft Failure Necessitating ECMO
he most common indication for ECMO was early graft
ailure (n  13, 57%), followed by pneumonia or sepsis
n  6, 26%) and acute rejection (n  4, 17%). Three
atients with early graft failure had left atrial anastomotic
omplications that caused pulmonary congestion and ne-
essitated reoperation. Another had important bleeding
rom dense pleural adhesions that led to high transfusion
equirement and multiple reoperations. All others (n  9)
ad severe graft failure of unclear etiology that could be
ermed “primary graft dysfunction”10; we elected to use
he term “early graft failure,” however, because of the
nclear etiology yet early temporal relationship to trans-
lantation. Three patients required ECMO for acute re-
ection, with 1 of the 3 requiring 2 separate ECMO runs.
cute rejection was diagnosed by transbronchial biopsy
nd treated with plasmapheresis and antithymocyte glob-
ABLE 1. Continued
haracteristic
Yes (
n* N
Blood type
O 22 1
A 22
B 22
AB 22
Rh factor
Positive 20 1
Negative 20
ransplant
Type of transplant
Single 22 1
Double 22 1
Cold ischemic time (min),† mean  SD 20 302 
BMI
Difference,‡ mean  SD 17 0.38
Ratio,§ mean  SD 17 1.02 
BSA
Difference,‡ mean  SD 17 0.03
Ratio,§ mean  SD 17 1 
Interval from 1/1/1990 to index
peration, mean  SD
22 9.6 
1A, Alpha-1a antitrypsin; BMI, body mass index; BSA, body surface area
VA, cerebrovascular accident; ECMO, extracorporeal membrane oxygen
Longest ischemic time if double lung transplant. ‡Recipient– donor. §Reclin. No patient underwent acute retransplantation. t
The Journal of Thoraciciming and Duration of ECMO
CMO was initiated at a median of 2 days postoperatively (range,
-21 days; 15th and 85th percentiles, 0 and 12 days; Figure 1). It
as instituted earliest for severe graft failure (generally within 2
ays of lung transplant), was instituted over a broad range of
iming for pneumonia or sepsis, but generally later than for severe
raft failure, and was concentrated within the second week for
cute rejection. ECMO was maintained for a median of 4 days
range, 2-17 days; 15th and 85th percentiles, 3 and 10 days; Figure
). Median duration was longest in the pneumonia/sepsis group (7
ays; P [Wilcoxon] for differences among groups .03). VA and
V ECMO were similarly effective in reducing pulmonary artery
ressures.
omplications of ECMO
wenty of 22 patients (90%) had at least 1 complication
irectly attributable to ECMO (Table 2). The most commonly
ccurring complications were renal failure necessitating dial-
sis (57%) and bleeding necessitating reoperation (43%).
omplications occurred with both VA and VV ECMO, with
imilar prevalence (P  .5). Complications were associated
ith both peripheral and central cannulation techniques, al-
ECMO
P
2) No (n  452)
% n* No. %
55 445 264 59 .7
32 445 142 32 .9
14 445 39 8.8 .4
0 445 0 0 —
90 439 369 84 .5
10 439 70 16 .5
55 450 256 57 .8
45 450 194 43 .8
363 280  145 .9
413 0.76 7.5 .9
413 1.01  0.3 .7
7 413 0.06 0.33 .6
413 0.99 0.18 .6
452 10 4.3 .7
, central nervous system; COPD, chronic obstructive pulmonary disease;
; PRA, panel reactive antibody; SD, standard deviation. *Data available.
t/donor.n  2
o.
2
7
3
0
8
2
2
0
175
8.2
0.29
0.3
0.19
4.7
; CNS
ationhough the small number of central cannulations (2) precluded
and Cardiovascular Surgery ● Volume 132, Number 4 957
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TXeaningful comparison. There were no deep vein thromboses
n either patient cannulated centrally.
urvival After ECMO
e compared survival after ECMO against survival of all
ther patients undergoing lung transplantation at Cleveland
linic between February 1990 and October 2005 (Figure 3,
). Initially, risk of death was substantially higher in the
CMO group, but patients surviving beyond 1 year had a
isk of death not importantly different from that of those not
laced on ECMO (Figure 3, B).
igure 1. Relation of indication for ECMO and its timing (interval
rom lung transplant to institution of ECMO). ECMO, extracorpo-
eal membrane oxygenation.
igure 2. Duration of ECMO according to etiology. ECMO, extra-
vorporeal membrane oxygenation.
58 The Journal of Thoracic and Cardiovascular Surgery ● Octoredictors of Mortality
f the 8 variables evaluated, the only 1 associated with
orse outcome was instituting ECMO for pneumonia or
epsis (Figure 4). Survival was similar in patients supported
or acute rejection and early graft failure.
iscussion
ost transplant centers perform ECMO for severe early graft
ailure (within 48 hours of transplant), because there is an
mpression that outcomes are poor for other indicators. Our
tudy focused on patients supported with ECMO beyond the
arly postoperative period and for extended indications.
rincipal Findings
Risk factors for severe graft failure leading to
CMO. We were unable to identify risk factors for severe
raft failure leading to ECMO after lung transplantation. This
ay be because graft failure severe enough to require ECMO
as uncommon, with a prevalence of only 4%. We were not
ble to reproduce results of others showing that recipient
iagnosis of primary pulmonary hypertension, mismatch of
onor and recipient size, or female gender were predictive of
eed for ECMO.4,11,12 Although PRA levels have been shown
o be predictive of survival after lung transplantation,13 they
ere not predictive of need for ECMO.
Etiology of graft failure necessitating ECMO. As in
ther studies, early graft failure was the most common
ndication for ECMO in our patients, followed by pneumo-
ia or sepsis. We agree with the movement to standardize
he term “primary graft dysfunction” to define lung injury
ccurring after graft implantation10 and are incorporating
his term prospectively. However, in this study, we used the
erm “early graft failure” because of our difficulty differen-
iating the role of transfusion requirement and pulmonary
ABLE 2. ECMO complications (n  23 among 22 patients)
omplication No.* % of 23
enal failure necessitating dialysis 13 57
leeding necessitating reoperation 10 43
eep vein thrombosis 5 22
erebrovascular accident 3 13
ower extremity ischemia 3 13
ommon femoral vein injury 2 8.6
eep vein thrombosis and pulmonary embolus 1 4.3
eparin-induced thrombocytopenia 1 4.3
emoptysis 1 4.3
ymphocele 1 4.3
asopharyngeal bleeding 1 4.3
ompartment syndrome requiring fasciotomy 1 4.3
trial fibrillation 1 4.3
Number of patients experiencing each complication; individual patients
ould experience more than 1 complication. ECMO, extracorporeal mem-
rane oxygenation.enous complications leading to ECMO in 3 patients.
ber 2006
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TXTiming and duration of ECMO. Our median timing
verall of initiating ECMO, postoperative day 2, was slightly
ater than recently reported series in which ECMO was almost
niversally initiated within the first 2 days of transplant.12,14
owever, this relates at least in part to our extended use of
CMO that, in comparison, resulted in instituting ECMO over
 wide range of postoperative days, with the latest being day
1. We have confirmed that patients can still be salvaged when
laced on ECMO later in their hospital course, particularly
hose experiencing acute rejection, although numbers are
mall.15 In addition, we have shown that survival is possible in
atients who require longer periods of ECMO support, with 1
atient being discharged alive from the hospital after 17 days
n ECMO.
Complications of ECMO. Nearly all our patients had
igure 3. Death after ECMO (open circles) and death in all others
fter lung transplant (closed circles). A, Survival. Each circle
epresents a death, vertical bars are asymmetric 68% confidence
ntervals for these estimates (equivalent to 1 standard error),
nd numbers in parentheses represent patients alive at various
ime points. Solid lines represent parametric estimates enclosed
ithin 68% confidence limits. B, Hazard function (instantaneous
isk of death), ECMO, extracorporeal membrane oxygenation.omplications directly attributable to ECMO. Complica- p
The Journal of Thoracions seem inherent in the ECMO circuit, primarily because
t requires large cannulas that are thrombogenic despite their
eparin coating and that can lead to distal limb malperfusion
nd thromboembolism. In addition, need for anticoagulation
o prevent or treat thromboembolism, as well as hemolysis
esulting from the ECMO circuit, predispose patients with
resh operative fields to bleeding. Bleeding complications
ere not directly related to level of anticoagulation and
ccurred in the face of normal thrombocyte counts.
We have become increasingly aggressive about diagnos-
ng and treating deep vein thrombosis and use inferior caval
lters after decannulation when proximal deep vein throm-
osis has been identified. Dialysis requirement reflects mul-
ifactorial injury to the kidneys that occurs secondarily to
emodynamic instability, vasopressor use, sepsis, direct ef-
ects of the ECMO circuit, and effects of multiple nephro-
oxic drugs. Although multiple antibiotics were used to treat
epsis, we did not alter our routine postoperative antifungal
herapy as prophylaxis for patients on ECMO.
Survival after ECMO. Survival after ECMO was reason-
ble and consistent with that of other reports, with salvage
ossible in a group of patients who would otherwise have died.
urvival was best in patients treated for early graft failure and
cute rejection. Interestingly, hazard curves for patients need-
ng ECMO versus those who did not became equivalent at 1
ear, suggesting that initial factors leading to ECMO and the
nsuing difficult postoperative course can be overcome with-
ut affecting long-term survival.
Predictors of mortality. Of the 8 variables evaluated as
redictors of mortality for patients requiring ECMO (Figure 3),
e were able to identify only 1: institution of ECMO for sepsis
r pneumonia. Other studies have suggested that VV was
igure 4. Survival after ECMO according to indication for ECMO.
ormat is similar to that of Figure 3, A, except closed circles
epresent ECMO for early graft failure and acute rejection, and
pen circles represent ECMO for pneumonia or sepsis, ECMO,
xtracorporeal membrane oxygenation.referable to VA ECMO,12 that the era in which ECMO was
ic and Cardiovascular Surgery● Volume 132, Number 4 959
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9
TXnstituted was a risk factor,3 and that instituting ECMO late
7 days) after transplant was almost never successful.5 /'
ultivariable analysis did not identify any of these factors as
redictors of mortality, although this may be due to small
umbers and confounding of multiple variables (for example,
iming of ECMO and etiology of graft failure leading to
CMO). Our study does support Meyers and colleagues’4
nding that outcomes were poor after ECMO use in infected
atients. Although our study showed similar outcomes of VA
nd VV ECMO, we have gravitated toward use of VV even in
he setting of pulmonary hypertension and hemodynamic com-
romise. Correction of acidosis, carbon dioxide clearance, and
mproved oxygenation provided by the VV circuit rapidly
ower pulmonary artery pressures and improve systemic he-
odynamics. We reserve VA ECMO for patients with high
asopressor requirements and imminent circulatory arrest.
imitations
he primary limitation of this study is that it represents
linical experience at a single center with low prevalence
f severe graft failure leading to ECMO. In addition,
iagnosing early graft failure, acute rejection, and pneu-
onia or sepsis can be difficult, and etiology may be
ultifactorial. Biopsy in the setting of severe hypoxia or
nticoagulation is frequently not possible, and positive
ultures can represent colonization as well as active
nfection. In addition, the criteria for VA versus VV
CMO were not well defined and were influenced by
ultiple factors, including hemodynamics, surgeon pref-
rence, and era of transplantation.
onclusions
ur study has shown that ECMO can be used with reason-
ble results to salvage patients with severe graft failure after
ung transplantation. We have learned to consider carefully
ll patients with severe graft failure for  ECM`O and t
xtend its use selectively past the initial perioperative pe-
iod, particularly to those with acute rejection.
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